Update Pharma to Present at the 15th Annual Rodman & Renshaw Global Investment Conference
RENO, Nev., Sept. 6, 2013 /PRNewswire/ -- Update Pharma Inc., today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference on September 10, 2013 at 3:15 pm in room 7-03 of the Millennium Hotel. The presentation will be webcast live, and the replay will remain available for 90 days at www.rodm.com.
John Rothman Ph.D., CEO, of Update Pharma, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors.
About Update Pharma Inc.:
Update Pharma Inc. is developing UPI-928. In the 1980's UPI-928 was developed by Lederle Laboratories in 44 phase 1, 2 and 3 clinical trials, including 33 clinical trials at the National Cancer Institute. Over 2000 treated patients demonstrated an acceptable safety profile and clinical activity that was documented in over 71 peer reviewed publications in which clinical utility was demonstrated in recurrent or regressive in leukemia, lymphoma, breast and ovarian cancers. The agent was approved for marketing in France for the treatment of acute myeloid leukemia (AML). However, Lederle was sold at about the time of the approval to Wyeth, who did not have a market presence in oncology. Development was stopped and, despite marketing approval, UPI-928 was never launched. Wyeth was sold shortly thereafter to Pfizer, who did not re-activate the program. Thus, despite a safety profile that was superior to related drugs and an extensive body of peer reviewed literature documenting clinical activity in a number of indications, UPI-928 was never marketed and was eventually forgotten.
Recent data has shown that UPI-928 also has significant immunologic and genomic mechanisms of action which contribute to the clinical utility of the agent. These include, for example, the ability to activate macrophages sufficient to eliminate tumors in an allogeneic model and the ability to bind DNA in a manner that displaces telomerase binding proteins and blocks the action of telomerase, enabling immortal cells to regain a mortal phenotype. This multi-factorial attack on cancer may ultimately make UPI-928 suited for combinatorial regimens in which chemotherapeutic agents are combined with immunologically active and/or genomically active agents.
Update has filed extensive for broad and deep patent protection on UPI-928 based upon the composition of new formulations with better aqueous solubility, new mechanisms of action, and methods of use that include use with symptom mitigating agents like Neulasta® and Neumega®, and combinatorial regimens with immuno-modulators or small molecules. The company intends to use existing regulatory mechanisms to accelerate the development process based upon the extensive body of historical data.
Certain statements in this Press Release are "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risk factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include the risk for the Company to complete its development work, as well as the risks inherent in commercializing a new product (including technology risks, market risks, financial risks and implementation risks, and other risks and uncertainties affecting the Company), as well as other risks that have been disclosed by us and are customarily disclosed in SEC filings of publicly traded pharmaceutical companies. We disclaim any intention or obligation to revise any forward-looking statements, including, without limitation, financial estimates, whether as a result of new information, future events, or otherwise.
Read more news from Update Pharma Inc.
SOURCE Update Pharma Inc.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.